Intellia Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NTLAAccesswire • 01/17/25
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the InvestigationAccesswire • 01/17/25
Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities InvestigationAccesswire • 01/16/25
Shareholders that lost money on Intellia Therapeutics, Inc. (NTLA) should contact Levi & Korsinsky about Securities Fraud Investigation - NTLAAccesswire • 01/15/25
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Reach OutAccesswire • 01/15/25
Lost Money on Intellia Therapeutics, Inc. (NTLA)? You May Have Been Affected by Fraud - Contact Levi & KorsinskyAccesswire • 01/14/25
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach OutAccesswire • 01/14/25
Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to ConnectAccesswire • 01/13/25
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock DownZacks Investment Research • 01/10/25
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)GlobeNewsWire • 01/09/25
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyGlobeNewsWire • 11/25/24
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?The Motley Fool • 11/22/24
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)Seeking Alpha • 11/19/24
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisGlobeNewsWire • 11/16/24